CTMX — CytomX Therapeutics, Inc.

Is CTMX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

CytomX Therapeutics, Inc. (CTMX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $1.99. The rating moved from Strong Oversold to Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

CytomX’s technology platform and partner relationships provide meaningful upside if clinical milestones are met, but the company’s valuation is highly dependent on trial progress and external financing. Near-term performance is likely to be driven by news flow (data readouts, partner milestones or financing announcements) rather than broad macro moves. Monitor upcoming clinical timelines, cash runway disclosures, and any partnership/milestone cadence for directional signals.

Key factors

  • Probody platform with differentiated targeted-antibody approach and partnered programs that provide readthrough and potential milestone revenue.
  • Early-stage clinical pipeline: upside tied to positive proof-of-concept/registration trial data but limited near-term commercial products.
  • Cash runway and financing posture are critical; prior small-cap biotech history suggests potential need for additional capital.
  • Collaborations with larger pharma provide validation and non-dilutive funding opportunities but also create milestone concentration risk.
  • Broad market environment favoring large-cap pharma and defensive flows reduces small-cap biotech investor appetite in the near term.
  • Convertible-debt and sector-level dilution pressures observed across biotech raise funding-cost and hedging concerns.

Risks

  • Clinical trial failure or negative readouts for lead programs, materially impacting valuation.
  • Insufficient cash runway leading to dilutive financings or unfavorable partnership terms.
  • Regulatory setbacks or slower-than-expected enrollment and development timelines.
  • Competitive pressure from other targeted-immunotherapy platforms and larger pharmas advancing similar modalities.
  • Low retail and institutional interest relative to large-cap pharma rotation, limiting liquidity and share-price support.
  • Dependence on partner milestones and external funding, concentrating execution risk outside the company’s direct control.

See today's live rating, score and targets

Members see the live hourly rating for CTMX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.